Your World, Fully Explored.
Get Started
SubscribeLogin
Israel-Hamas Conflict
Eurovision
Social Media
Soccer
Donald Trump
Formula 1
Natural Disasters
South America
Artificial Intelligence
European Union
World Cup
Manchester United
Vladimir Putin
Published • loading... • Updated

Iza-Bren Shows Preliminary Efficacy, Safety in Heavily Pretreated HER2–/HER2-low Breast Cancer

Summary by onclive.com
Iza-bren was safe and displayed early clinical activity in patients with heavily pretreated breast cancer across both HER2-low and HER2-negative subgroups.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

All
Left
Center
Right
onclive.comonclive.com

Iza-Bren Shows Preliminary Efficacy, Safety in Heavily Pretreated HER2–/HER2-low Breast Cancer

Iza-bren was safe and displayed early clinical activity in patients with heavily pretreated breast cancer across both HER2-low and HER2-negative subgroups.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

onclive.com broke the news in on Friday, May 16, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Breast Cancer

Breast Cancer

News
For You
SearchBlindspotLocal